Efficacy and safety of ledipasvir/sofosubuvir/ribavirin combination therapy for failures to daculatasvir/asunaprevir combination therapy.
Not Applicable
- Conditions
- Patients infected with HCV genotype 1, who failed to daculatasvir/asunaprevir comnination therapy.
- Registration Number
- JPRN-UMIN000022418
- Lead Sponsor
- Toranomon Hospital, Department of Hepatology.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with history of hypersensitivity to HCV NS5A inhibitors/ NS5B inhibitors/ ribavirin. 2) Patients with hepatocellular carcinoma. 3) Females who are pregnant or lactating. 4) Patients with renal dysfunction (eGFR <50 mL/min/1.73m2) and hemodialysis patients. 5) Unsuitable patients for this study who were evaluated by principal investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method